Vitamin B6: too much, too little, too late? An analysis of sales trends in Australia from 2023 to 2025
Internal Medicine Journal · 26.07.2026
DOI: 10.1111/imj.70589 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 26.07.2026. Verfasst von Wai-Jo Jocelin Chan und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Peripheral neuropathy associated with vitamin B6 (pyridoxine) is dose and duration dependent. High‐dose vitamin B6 products associated with adverse neurological effects are available in Australia, prompting recent regulatory action to reschedule products containing ≥50 mg pyridoxine to schedule 3 (pharmacist only).
Aims
This study examined real‐world consumer purchasing behaviours of vitamin B6 products in Australian pharmacies to identify high‐risk purchasing patterns (e.g. large doses, multiple products, stockpiling behaviours).
Methods
Sales data from the IQVIA Consumer Health Basket Database (1 August 2022–31 July 2025), representing ~75% of national pharmacy‐based complementary medicines sales were analysed. Listed medicines on the Australian Register of Therapeutic Goods providing a daily dose of ≥5 mg total equivalent pyridoxine were included ( n = 792). Analysis included unit sales, combined total maximum daily dosage per transaction and duplicate purchases as a proxy for ongoing use.
Results
A total of 20.32 million products (≥5 mg) were sold across 15.8 million transactions. Products containing 10–49 mg dominated sales with 11.0 million (54.20%) unit sales, and ≥50 mg doses accounted for 3.40 million (16.75%) units and 3.4 million (21.63%) of all transactions. Multiple products or duplicate purchases occurred in 1.2 million (7.73%) and 1.58 million (9.17%) transactions respectively. Sales were otherwise stable, except for the 2023 withdrawal of >100 mg products.
Conclusion
Large volumes of vitamin B6 products containing doses above the recommended intake continue to be purchased in Australia, including through combinations of lower‐dose products that will not be affected by proposed rescheduling. The implementation period for scheduling extends the potential for stockpiling, meaning that high‐risk exposure will persist without strengthened risk communication.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
- School of Health Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
- Health Research Group Pty Limited, Sydney, New South Wales, Australia.
- IQVIA Australia, Sydney, New South Wales, Australia.
ORCID-Profile: Rose Cairns, Joanna E Harnett
Zitieren
APA
Chan, W. J., Hunter, J., Lee, V. Y., Cairns, R., Mathews, S., & Harnett, J. E. (2026). Vitamin B6: too much, too little, too late? An analysis of sales trends in Australia from 2023 to 2025. Internal Medicine Journal. https://doi.org/10.1111/imj.70589
Vancouver
Chan WJ, Hunter J, Lee VY, Cairns R, Mathews S, Harnett JE. Vitamin B6: too much, too little, too late? An analysis of sales trends in Australia from 2023 to 2025. Internal Medicine Journal. 2026. doi:10.1111/imj.70589
BibTeX
@article{Chan2026,
author = {Chan, Wai-Jo Jocelin and Hunter, Jennifer and Lee, Vivian Yeukman and Cairns, Rose and Mathews, Slade and Harnett, Joanna E},
title = {Vitamin B6: too much, too little, too late? An analysis of sales trends in Australia from 2023 to 2025},
journal = {Internal Medicine Journal},
year = {2026},
doi = {10.1111/imj.70589}
}
EUVIMED